Key facts
- This page summarizes Joseph Ciaffoni's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Dec 2023, 16:36.
Joseph Ciaffoni - 21 Dec 2023 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- COLL
- Reported as of
- 21 Dec 2023
- Net transaction value
- -$39,398
- SEC form
- 4
- Accepted by SEC
- 22 Dec 2023, 16:36:26 UTC
- Prior SEC filing
- 20 Dec 2023
- Next SEC filing
- 14 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Colleen Tupper as Attorney-In-Fact For Joseph Ciaffoni
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joseph Ciaffoni filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 22 Dec 2023.
Change
- Previous filing in this sequence was filed on 20 Dec 2023.
- Current net transaction value: -$39,398.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
COLL
transaction
Common Stock
Options Exercise
- Transaction value
- $92,978
- Shares
- +4,357
- Change %
- +1.6%
- Price
- $21.34
- Shares after
- 279,357
- Date
- 21 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
COLL
transaction
Common Stock
Sale
- Transaction value
- $132,377
- Shares
- -4,357
- Change %
- -1.6%
- Price
- $30.38
- Shares after
- 275,000
- Date
- 21 Dec 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
COLL
transaction
Derivative
Stock Option (Right to Purchase)
Options Exercise
- Transaction value
- $0
- Shares
- -4,357
- Change %
- -21%
- Price
- $0.000000
- Shares after
- 16,875
- Date
- 21 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,357
- Exercise price
- $21.34
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023.
Footnote F2
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.13 to $30.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer.